0001828316-26-000015
SEC filingPharming advanced its U.S.-centric commercial strategy with revenue growth from increased patients on paid therapy, while pursuing pipeline expansion through the Abliva acquisition and scaling R&D investments amid expected future cost increases.
In Item 1 - Business, Pharming emphasized shaping an efficient and scalable organization throughout 2025. This operating model supports anticipated sustained portfolio growth, disciplined capital allocation, and preparations for future product launches. The focus addresses the need to balance commercial scaling with innovation, particularly as cross-border data restrictions in Europe and beyond could raise operational costs and complexity for global service delivery.
The Abliva acquisition marked a key strategic move, adding intangible assets for KL1333 and goodwill to expand into mitochondrial diseases. This deal aligns with elevated R&D commitments, positioning Pharming to advance clinical candidates despite pressures from rising expenses. Management's Item 7 commentary highlights leadership enhancements, including the January 2026 appointment of Chief Commercial Officer Leverne, who brings over 30 years of experience from Novartis and Dexcom in product launches, strategy, and international growth. Her role will drive global commercial strategy across market access, marketing, sales, and lifecycle management.